Vericel’s high-barrier MACI franchise is converting 20%+ growth into cash flow, but premium valuation leaves execution, reimbursement, and manufacturing risks highly consequential.
Overview
Vericel Corporation (VCEL) is a commercial-stage regenerative medicine company selling three differentiated products: MACI for knee cartilage repair, Epicel for catastrophic burns, and NexoBrid for enzymatic burn debridement. Revenue is concentrated in MACI at approximately 82% of product sales, but all products address specialized clinical needs with substantial regulatory, manufacturing, and workflow barriers. **The financial trajectory is inflecting positively:** Q2 2026 revenue increased 22% to $77.46 million, MACI revenue rose 23% to a record $65.50 million, and the company reported its first profitable second quarter, with GAAP net income of $2.21 million. Free cash flow reached $14.30 million, the fourth consecutive quarter above $12 million. Management raised FY 2026 revenue guidance to $330–340 million and reaffirmed approximately 75% gross and 27% adjusted EBITDA margins. **The long-term opportunity combines MACI Arthro, a potential U.K. launch by 2027, the $1 billion ankle opportunity, and BARDA procurement.** At approximately $46.23, valuation is demanding at 99.44x P/E and 7.7x EV/Sales, but the report’s probability-weighted five-year target is $80.84.